Releases - Biotage

View:
 

Found press releases

 

Year-end report  January - December 2011

2/9/2012 2:00 AM EST
Fourth quarter 2011

· Net sales are unchanged and are reported at 116.0 MSEK (116.1). At comparable exchange rates sales increased by 3 percent
· The operating result amounted to 9.8 MSEK (-435.9)1)
· A 7.3 MSEK (15.0) additional purchase payment for the Biosystems business area divested in 2008 was received from Qiagen
· The result after tax amounted to 17.2 MSEK (-424.8)1)
· Earnings per share amounted to...

Biotage is subject to extended patent litigation in the US

1/12/2012 2:00 AM EST
Biotage AB has together with its subsidiaries Biotage GB Ltd and Biotage LLC (collectively “Biotage”) been sued for patent infringement of the US patents no 8,066,875 B2 and 8,070,957 in the U.S. District court for the Southern District of California. The lawsuit has been filed by Scientific Plastic Products, Inc.

These lawsuits relate to the same patent family (US patents 7,138,061, 7,381,327 and 7,410,571) that...

Changes in Management of Biotage AB

10/26/2011 2:00 AM EST
Erika Söderberg Johnson has been appointed as the new CFO and Business Controller of Biotage AB. She will start her assignment on 1 January 2012. Erika has been the CFO of Karo Bio AB since 2007.

Mats-Olof Wallin, the present CFO of Biotage, is leaving the company at his own request and he remains at his position until Erika Söderberg Johnson starts. Mats-Olof started as CFO at Pyrosequencing AB (which later was...

Interim report January - September 2011

10/26/2011 2:00 AM EST
Third quarter, July – September 2011

· Group net sales amounted to 106.6 MSEK (109.5). The organic growth in the quarter was 5 percent.
· The operating result amounted to 10.9 MSEK (4.8).
· The result after tax amounted to 11.4 MSEK (4.7).
· Earnings per share amounted to 0.15 SEK (0.06).
· The cash flow from operating activities was 13.7 MSEK (7.0).
· Net cash at September 30, 2011 amounted to 181.6 MSEK,...

Biotage AB Nomination Committee

10/26/2011 2:00 AM EST
A Nomination Committee consisting of shareholder representatives and the Chairman of the Board of Directors has been formed for Biotage AB. The Nomination Committee shall, before the Annual General Meeting 2012, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, election of Auditors, the determination of fees and matters...

Following Biotage’s request for re-examination US Patent and Trademark Office ha...

9/8/2011 3:00 AM EST
A lawsuit was filed against Biotage by Scientific Plastic Products, Inc. concerning alleged infringement of the US patents no 7,138,061, 7,381,327 and 7,410,571.

Biotage then filed an application to the US Patent and Trademark Office applying for re-examination of all patent claims in the three patents mentioned above. At the same time Biotage submitted a request to stay the lawsuit in the district court pending...

Interim report January - June 2011

8/17/2011 2:00 AM EST
Interim report January - June 2011

· Group net sales amounted to 98.6 MSEK (103.5) in the second quarter and to 205.8 MSEK (203.4) in the period January – June. At comparable exchange rates net sales increased by 8 percent in the quarter and by 12 percent the first six months.
· The operating result amounted to 1.8 MSEK (7.6) in the second quarter and to 4.4 (MSEK 12.3) in the period January - June.
· The result...

Following Biotage’s request for re-examination US Patent and Trademark Office ha...

5/9/2011 8:00 AM EST
A lawsuit was filed against Biotage by Scientific Plastic Products, Inc. concerning alleged infringement of the US patents no 7,138,061, 7,381,327 and 7,410,571.

Biotage then filed an application to the US Patent and Trademark Office applying for re-examination of all patent claims in the three patents mentioned above. At the same time Biotage submitted a request to stay the lawsuit in the district court pending...

Biotage AB launches share buy-back

5/6/2011 2:30 AM EST
The board of directors of Biotage AB (publ) has resolved to start a share buy-back program in accordance with the Annual General Meeting’s resolution to authorize the board to decide on the acquisition and sale of the company’s own shares.
At the Annual General Meeting held on 27 April 2011, the board was authorized to decide on the acquisition and sale of the company’s own shares up and until the forthcoming...

Resolutions at the Annual General Meeting in Biotage AB on April 27, 2011

4/27/2011 11:30 AM EST
At the Annual General Meeting held in Biotage AB (Reg. No. 556539-3138) on April 27, 2011, the following resolutions were passed, among others.

Appropriation of the company’s result

The General Meeting resolved a dividend of SEK 0.25 per share, which in aggregate is a dividend in the amount of no higher than SEK 19.909.422.

Record date for dividend was resolved to be Monday, 2 May 2011.

Board of...

Biotage

Biotage accelerates the drug discovery and development process and increases the knowledge of the importance of the genetic make-up by providing complete solutions for medicinal chemistry research and applied genetic ana...

View more


  CONTACT